Your browser doesn't support javascript.
Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19.
Kang, Dong-Hoon; Na, Joo-Young; Yang, Jun-Ho; Moon, Seong-Ho; Kim, Sung-Hwan; Jung, Jae-Jun; Cha, Ho-Jeong; Ahn, Jong-Hwa; Park, Yong-Whi; Cho, Sang-Yeong; Yu, Ho-Kyung; Lee, Soo-Hee; Park, Mi-Yeong; Kim, Jong-Woo; Byun, Joung-Hun.
  • Kang DH; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Na JY; Department of Forensic Medicine, Pusan National University School of Medicine, Yangsan 50612, Korea.
  • Yang JH; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Moon SH; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Kim SH; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Jung JJ; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Cha HJ; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Ahn JH; Department of Internal Medicine, Gyeongsang National University College of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • Park YW; Department of Internal Medicine, Gyeongsang National University College of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • Cho SY; Department of Internal Medicine, Gyeongsang National University College of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • Yu HK; Department of Anesthesiology and Pain Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • Lee SH; Department of Anesthesiology and Pain Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • Park MY; Department of Anesthesiology and Pain Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon 51472, Korea.
  • Kim JW; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
  • Byun JH; Department of Thoracic and Cardiovascular Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11, Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea.
Medicina (Kaunas) ; 58(3)2022 Mar 20.
Article in English | MEDLINE | ID: covidwho-1760771
ABSTRACT
A 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19. She had no history of severe acute respiratory syndrome coronavirus-2 infection. She did not exhibit clinical signs or have laboratory findings of concomitant infection before or after vaccination. Heart transplantation was performed because her heart failed to recover with venoarterial extracorporeal oxygenation support. Organ autopsy revealed giant cell myocarditis, possibly related to the vaccines. Clinicians may have to consider the possibility of the development of giant cell myocarditis, especially in patients with rapidly deteriorating cardiac function and myocarditis symptoms after COVID-19 vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Myocarditis Type of study: Case report / Experimental Studies / Prognostic study Topics: Vaccines Limits: Female / Humans / Middle aged Language: English Journal subject: Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Myocarditis Type of study: Case report / Experimental Studies / Prognostic study Topics: Vaccines Limits: Female / Humans / Middle aged Language: English Journal subject: Medicine Year: 2022 Document Type: Article